Supplies of the old presentation expired at the end of July and stocks of the new 6mg per ml presentation are expected to become available in early October. Should the product be required in the interim period, Roche directs prescribers to sections 4.2 and 6.6 of the SPCs for Tamiflu Capsules, which describe the preparation of suitable dosage forms when the powder for suspension is unavailable.
Tamiflu is licensed for the treatment and prevention of influenza when the virus is circulating in the community.
View Tamiflu drug record
Further information: Roche